Trial Profile

A phase I clinical study assessing RXC008

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RXC 008 (Primary)
Indications Crohn's disease
Focus Adverse reactions

Most Recent Events

07 Feb 2024 According to a Redx Pharma media release, a Clinical Trial Application (CTA) of RXC008 was submitted during Q4 2023.
23 Feb 2023 According to a Redx Pharma media release, company progressing towards a CTA/IND application at the end of 2023 and this trial is expected to start in H1 2024
22 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com